Hasil Pencarian - Marta Krejci

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

    Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse oleh Ludek Pour, Sabina Sevcikova, Henrieta Greslikova, Renata Kupska, Petra Majkova, Lenka Zahradova, Viera Sandecka, Zdenek Adam, Marta Krejci, Petr Kuglik, Roman Hajek

    Diterbitkan 2014-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.

    Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. oleh Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, Petr Kuglik, Martina Almasi, Miroslav Penka, Marta Krejci, Zdenek Adam, Ludek Pour, Sabina Sevcikova, Roman Hajek

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

    P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS oleh Tereza Popková, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Petr Pavlíček, Tomas Jelínek, Marta Krejčí, Jan Straub, Vladimir Maisnar, Tereza Dekojová, Tomáš Pika, Jan Soukup, Lenka Pospíšilová, Roman Hájek

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease

    Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease oleh Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.

    Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neurop... oleh Jiri Minarik, Petr Pavlicek, Ludek Pour, Tomas Pika, Vladimir Maisnar, Ivan Spicka, Jiri Jarkovsky, Marta Krejci, Jaroslav Bacovsky, Jakub Radocha, Jan Straub, Petr Kessler, Marek Wrobel, Lenka Walterova, Michal Sykora, Jarmila Obernauerova, Lucie Brozova, Evzen Gregora, Dagmar Adamova, Jaromir Gumulec, Zdenek Adam, Vlastimil Scudla, Roman Hajek, Czech Myeloma Group

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

    Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes oleh Louise de Swart, Chloé Reiniers, Timothy Bagguley, Corine van Marrewijk, David Bowen, Eva Hellström-Lindberg, Aurelia Tatic, Argiris Symeonidis, Gerwin Huls, Jaroslav Cermak, Arjan A. van de Loosdrecht, Hege Garelius, Dominic Culligan, Mac Macheta, Michail Spanoudakis, Panagiotis Panagiotidis, Marta Krejci, Nicole Blijlevens, Saskia Langemeijer, Jackie Droste, Dorine W. Swinkels, Alex Smith, Theo de Witte

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

    Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM)... oleh Holger W. Auner, Simona Iacobelli, Giulia Sbianchi, Cora Knol-Bout, Didier Blaise, Nigel H. Russell, Jane F. Apperley, David Pohlreich, Paul V. Browne, Guido Kobbe, Cecilia Isaksson, Stig Lenhoff, Christof Scheid, Cyrille Touzeau, Esa Jantunen, Achilles Anagnostopoulos, Ibrahim Yakoub-Agha, Alina Tanase, Nicolaas Schaap, Wieslaw Wiktor-Jedrzejczak, Marta Krejci, Stefan O. Schönland, Curly Morris, Laurent Garderet, Nicolaus Kröger

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: